1-2 of 2
Keywords: Pcsk9
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease

Lauretta D. Low, Liangjian Lu, Chang-Yien Chan, Jinmiao Chen, Henry H. Yang, Hanry Yu, Caroline G.L. Lee, Kar-Hui Ng, Hui-Kim Yap
Journal: Clinical Science
Clin Sci (Lond) (2020) 134 (2): 225–237.
https://doi.org/10.1042/CS20190961
Published: 27 January 2020
... hypercholesterolemia and proteinuria was first identified. Plasma proprotein convertase subtilisin/kexin type 9 (Pcsk9) and liver ATP-binding cassette sub-family G member 5 (Abcg5) were measured using ELISA. Liver Ldlr and liver X receptor alpha (Lxra) were quantified with Western blot. Abcg5-mediated cholesterol...
View article titled, IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease
Open the PDF for IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease in another window
Includes: Supplementary data
Articles

PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate

Mikaël Croyal, Thi-Thu-Trang Tran, Rose Hélène Blanchard, Jean-Christophe Le Bail, Elise F. Villard, Bruno Poirier, Audrey Aguesse, Stéphanie Billon-Crossouard, Stéphane Ramin-Mangata, Valentin Blanchard, Brice Nativel, Kévin Chemello, Ilya Khantalin, Aurélie Thedrez, Philip Janiak, Michel Krempf, Christophe Boixel, Gilles Lambert, Etienne Guillot
Journal: Clinical Science
Clin Sci (Lond) (2018) 132 (10): 1075–1083.
https://doi.org/10.1042/CS20180040
Published: 31 May 2018
...; Christophe Boixel; Gilles Lambert; Etienne Guillot Therapeutic antibodies targeting proprotein convertase subtilisin kexin type 9 (PCSK9) (e.g. alirocumab) lower low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in clinical trials. We recently showed that PCSK9 enhances...
View article titled, <span class="search-highlight">PCSK9</span> inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
Open the PDF for <span class="search-highlight">PCSK9</span> inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate in another window
Includes: Supplementary data